Engineered TCRs use naturally occurring or slightly modified T cell receptors that can bind to antigens displayed by MHC molecules on tumor cells, whereas CAR-T cell therapy employs an artificial receptor that combines the antigen-binding component of an antibody with the signaling part of a TCR. Here, HLA-C is linked to neoplasm.